SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference – Orlando, FL Presentation on March 3rd at 8:05 a.m. Eastern Time Leerink Partners Global Health Conference – Miami, FL Fireside chat on March 9th at 10:40 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by vi.

Illinois Municipal Retirement Fund acquired a new position in shares of Veracyte, Inc. (NASDAQ: VCYT) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 40,318 shares of the biotechnology company's stock, valued at approximately $1,384,000. Illinois Municipal Retirement Fund owned about

VCYT heads into Q4 earnings with rising estimates, strong Decipher and Afirma volumes, and revenues seen up nearly 17% year over year.

The heavy selling pressure might have exhausted for Veracyte (VCYT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Veracyte (VCYT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Amalgamated Bank boosted its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 755.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,760 shares of the biotechnology company's stock after buying an additional 20,099 shares during the period. Amalgamated Bank's

Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.